Risk of recurrent venous thromboembolism in patients with the factor V Leiden (FVR506Q) mutation: Effect of warfarin and prediction by precipitating factors

British Journal of Haematology

Volumn 100, Issue 4, 1998, Pages 764-768

  Baglin, Caroline ^b   Brown, Karen ^b   Luddington, Roger ^b   Baglin, Trevor ^a  

^a CAMBRIDGE UNIVERSITY HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

^b NONE

Author keywords

Factor V Leiden; Precipitating factors; Thromboembolism; Warfarin

Indexed keywords

BLOOD CLOTTING FACTOR 5; WARFARIN;

ADULT; ANTICOAGULATION; ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; GENE MUTATION; HETEROZYGOTE; HOMOZYGOTE; HUMAN; IDIOPATHIC DISEASE; MAJOR CLINICAL STUDY; MALE; ORAL DRUG ADMINISTRATION; PREDICTION; PRIORITY JOURNAL; RECURRENT DISEASE; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; THROMBOEMBOLISM; THROMBOPHILIA; VEIN THROMBOSIS;

ADOLESCENT; ADULT; ANTICOAGULANTS; CHILD; FACTOR V; FEMALE; HETEROZYGOTE; HOMOZYGOTE; HUMANS; MALE; MIDDLE AGED; MUTATION; RECURRENCE; THROMBOEMBOLISM; TIME FACTORS; WARFARIN;

EID: 0031929806     PISSN: 00071048     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2141.1998.00632.x     Document Type: Article

References (16)

1. Baglin, T., Brown, K., Williamson, D., Baker, P. & Luddington, R. (1997) Relative risk of pulmonary embolism and deep vein thrombosis in association with the factor V Leiden mutation in a United Kingdom population. (Letter). Thrombosis and Haemostasis, 77, 1219.
2. Beauchamp, N., Daly, M., Hampton, K., Cooper, P., Preston, F. & Peake, I. (1994) High prevalence of a mutation in the factor V gene within the U.K. population: relationship to activated protein C resistance and familial thrombosis. British Journal of Haematology, 88, 219-222.
3. Brown, K., Williamson, D., Luddington, R., Baker, P. & Baglin, T. (1997) Risk of venous thromboembolism associated with a G to A transition at position 20210 in the 3′-untranslated region of the prothrombin gene. British Journal of Haematology, 98, 907-909.
4. Hille, E., Westendorp, R., Vandenbroucke, J. & Rosendaal, F. (1997) Mortality and causes of death in families with the factor V Leiden mutation (resistance to activated protein C). Blood, 89, 1963-1967.
5. Hull, R., Hirsh, J., Jay, R., Carter, C., England, C., Gent, M., Turpie, A., McLoughlin, D., Dodd, P., Thomas, M., Raskob, G. & Ockelford, P. (1982) Different intensities of oral anticoagulant therapy in the treatment of proximal-vein thrombosis. New England Journal of Medicine, 307, 1676-1681.
6. Lee, L., Jennings, I., Luddington, R. & Baglin, T. (1994) Markers of thrombin and plasmin generation in patients with inherited thrombophilia. Journal of Clinical Pathology, 47, 631-634.
7. Levine, M., Hirsh, J., Gent, M., Arnold, A., Warr, D., Falanga, A., Samosh, M., Bramwell, V., Pritchard, K., Stewart, D. & Goodwin, P. (1994) Double-blind randomised trial of a very-low-dose warfarin for prevention of thromboembolism in stage IV breast cancer Lancet, 343, 886-869.
8. Manten, B., Westendorp, R., Koster, T., Reitsma, P. & Rosendaal, F. (1996) Risk factor profiles in patients with different clinical manifestations of venous thromboembolism: a focus on the factor V Leiden mutation. Thrombosis and Haemostasis, 76, 510-513.
9. Palareti, G., Leali, N., Coccheri, S., Poggi, M., Manotti, C., D'Angelo, A., Pengo, V., Erba, N., Moia, M., Ciavarella, N., Devoto, G., Berettini, M., Musolesi, S., and on behalf of the Italian Study on Complications of Oral Anticoagulant Therapy (1996) Bleeding complications of oral anticoagulant treatment: an inceptioncohort. prospective collaborative study (ISCOAT). Lancet, 348, 423-428.
10. Poller, L., McKernan, A., Thomson, J., Elstein, M., Hirsch, P. & Jones, J. (1987) Fixed minidose warfarin: a new approach to prophylaxis against venous thrombosis after major surgery. British Medical Journal, 295, 1309-1312.
11. Poort, S., Rosendaal, F., Reitsma, P. & Bertina, R. (1996) A common genetic variation in the 3′-untranslated region of the prothrombin gene is associated with elevated prothrombin levels and an increase in venous thrombosis. Blood, 88, 3698-3693.
12. Prandoni, P., Lensing, A., Cogo, A., Cuppini, S., Villalta, S., Carta, M., Cattelan, A., Polistena, P., Bernardi, E. & Prins, M. (1996) The long-term clinical course of acute deep vein thrombosis. Annals of Internal Medicine, 125, 1-7.
13. Ridker, P., Miletich, J., Stampfer, M., Goldhaber, S., Lindpaintner, K. & Hennekens, C. (1995) Factor V Leiden and risks of recurrent idiopathic venous thromboembolism. Circulation, 92, 2800-2802.
14. Rintelen, C., Pabinger, I., Knobl, P., Lechner, K. & Mannlialter, C. (1996) Probability of recurrence of thrombosis in patients with and without factor V Leiden. Thrombosis and Haemostasis, 75, 229-232.
15. Rosendaal, F., Koster, T., Vandenbrouck, J. & Reitsma, P. (1995) High risk of thrombosis in patients homozygous for factor V Leiden (activated protein C resistance). Blood, 85, 1504-1508.
16. Simioni, P., Prandoni, P., Lensing, A., Scudeller, A., Sardella, C., Prins, M., Villalta, S., Dazzi, F. & Girolami, A. (1997) The risk of recurrent venous thromboembolism in patients with an Arg 506 to Gln mutation in the gene for factor V (factor V Leiden). New England Journal of Medicine, 336, 399-403.